Related trials
ATOLL, 2010 - enoxaparin vs standard heparin
TRA-PCI, 2009 - SCH 530348 vs placebo
NAPLES (Tavano), 2009 - bivalirudin vs actionated heparin plus tirofiban
CHAMPION-PCI, 2009 - cangrelor up front vs clopidogrel up front
CHAMPION-PLATFORM, 2009 - cangrelor up front vs delayed clopidogrel
ISAR-REACT 3, 2008 - bivalirudin vs UFH
HORIZONS-AMI (Stone), 2008 - bivalirudin vs heparin + GP2b3a inhibitors
STEEPLE, 2006 - enoxaparin vs UFH
ACUITY (Stone) (bivalirudin alone), 2006 - bivalirudin vs heparin + GP2b3a inhibitors
JUMBO-TIMI 26, 2005 - prasugrel vs clopidogrel
REPLACE-1, 2004 - bivalirudin vs UFH
Natarajan (without antiGp2b3a), 2003 - Dalteparin vs UFH
REPLACE-2, 2003 - bivalirudin vs hepatin + anti Gp2b3a
CRUISE, 2003 - Enoxaparin vs UFH
Natarajan (+ antiGp2b3a), 2003 - Dalteparin vs UFH + anti Gp2b3a
Petronio, 2002 - Abciximab vs placebo
Tamburino, 2002 - Abciximab vs placebo
Kleiman, 2002 - bivalirudin + eptifibatide vs heparin + eptifibatide
CADILLAC, 2002 - Abciximab vs placebo
Galeote, 2001 - Enoxaparin vs UFH
Drozd, 2001 - Enoxaparin vs UFH
Kini, 2001 - Abciximab vs placebo
Dubek b (+abciximal), 2001 - Enoxaparin+abciximab vs UFH
ADMIRAL, 2001 - Abciximab vs placebo
ESPRIT, 2000 - Eptifibatide vs placebo
See also:
All percutaneous coronary intervention clinical trials
All clinical trials of antithrombotics
All clinical trials of aspirin + dipyridamol
|
|
Treatments
Studied treatment |
ticlopidine 500, aspirin 650 + D225
|
Control treatment |
|
Patients
Method and design
Randomized effectives |
245 / 254 (studied vs. control) |
Design |
Parallel groups |
Follow-up duration |
6m |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
Non fatal stroke
0 / 245
1 / 254
classic
0,21 [0,00;15,14]
Vascular events
16 / 245
12 / 254
classic
1,38 [0,67;2,86]
Non fatal MI
14 / 245
10 / 254
classic
1,45 [0,66;3,21]
Vascular death
2 / 245
1 / 254
classic
2,07 [0,19;22,72]
Non vascular death
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Ref |
Studied treat. |
Control treat. |
Non fatal stroke
|
0 / 245 (0,2%) |
1 / 254 (0,4%) |
0,52 |
[0,02;15,38] |
|
|
Vascular events
|
16 / 245 (6,5%) |
12 / 254 (4,7%) |
1,38 |
[0,67;2,86] |
|
|
Non fatal MI
|
14 / 245 (5,7%) |
10 / 254 (3,9%) |
1,45 |
[0,66;3,21] |
|
|
Vascular death
|
2 / 245 (0,8%) |
1 / 254 (0,4%) |
2,07 |
[0,19;22,72] |
|
|
The primary endpoint (if exists) appears in blod characters
|
Reference(s) used for data extraction:
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
Vascular events |
6,53% |
4,72% |
1,8%
|
Non fatal MI |
5,71% |
3,94% |
1,8%
|
Vascular death |
8,16‰ |
3,94‰ |
4,2‰
|
Meta-analysis of all similar trials:
antithrombotics in percutaneous coronary intervention for all type of patients
Reference(s)
-
White CW, Chaitman B, Knudtson ML, Chisholm RJ, and the Ticlopidine Study Group..
Antiplatelet agents are effective in reducing the acute ischemic complications of angioplasty but do not prevent restenosis:
results from the ticlopidine trial.
Coronary Artery Dis 1991;2:757-67
Pubmed
|
Hubmed
| Fulltext
|